ADV6209 for Premedication in Pediatric Anesthesia: A Double-Blinded, Randomized Controlled Trial

ADV6209, a new formulation of midazolam with the addition of γ-cyclodextrin for oral use, has recently been licensed as the first pediatric sedative in the European Union. We compared the clinical efficacy of ADV6209 to the standard formulation of midazolam in premedication to reduce anxiety in chil...

Descripción completa

Detalles Bibliográficos
Autores principales: Zadrazil, Markus, Marhofer, Peter, Schmid, Werner, Marhofer, Daniela, Opfermann, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608962/
https://www.ncbi.nlm.nih.gov/pubmed/36297495
http://dx.doi.org/10.3390/pharmaceutics14102062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608962/
https://www.ncbi.nlm.nih.gov/pubmed/36297495
http://dx.doi.org/10.3390/pharmaceutics14102062

Ejemplares similares